115 related articles for article (PubMed ID: 16821592)
21. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
Rudas M; Filipits M; Taucher S; Stranzl T; Steger GG; Jakesz R; Pirker R; Pohl G
Breast Cancer Res Treat; 2003 Sep; 81(2):149-57. PubMed ID: 14572157
[TBL] [Abstract][Full Text] [Related]
22. Markers of drug resistance in relapsing colon cancer.
Lazaris AC; Kavantzas NG; Zorzos HS; Tsavaris NV; Davaris PS
J Cancer Res Clin Oncol; 2002 Feb; 128(2):114-8. PubMed ID: 11862483
[TBL] [Abstract][Full Text] [Related]
23. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Trudel D; Labbé DP; Araya-Farias M; Doyen A; Bazinet L; Duchesne T; Plante M; Grégoire J; Renaud MC; Bachvarov D; Têtu B; Bairati I
Gynecol Oncol; 2013 Nov; 131(2):357-61. PubMed ID: 23988418
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
25. [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
Chen AP; Zhang J; Liu H; Zhao SP; Dai SZ; Sun XL
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):48-52. PubMed ID: 19538870
[TBL] [Abstract][Full Text] [Related]
26. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
J Pharm Sci; 2008 Jun; 97(6):2045-8. PubMed ID: 17828752
[TBL] [Abstract][Full Text] [Related]
27. [Human pituitary tumor transforming gene 1 expression in ovarian carcinoma and its clinical significance].
Cheng YX; Feng J; Zhang XY; Fu TY; Yao Y
Ai Zheng; 2004 Sep; 23(9):1026-30. PubMed ID: 15363195
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
29. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Špaček J
Ceska Gynekol; 2015 Dec; 80(6):405-13. PubMed ID: 26741154
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract][Full Text] [Related]
33. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
Moore KN; Moxley KM; Fader AN; Axtell AE; Rocconi RP; Abaid LN; Cass IA; Rose PG; Leath CA; Rutledge T; Blankenship D; Gold MA
Gynecol Oncol; 2007 Dec; 107(3):398-403. PubMed ID: 17997146
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies.
Oue T; Yoneda A; Uehara S; Yamanaka H; Fukuzawa M
J Pediatr Surg; 2009 Feb; 44(2):377-80. PubMed ID: 19231538
[TBL] [Abstract][Full Text] [Related]
35. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
37. Distinct subtypes of serous ovarian carcinoma identified by p53 determination.
Lassus H; Leminen A; Lundin J; Lehtovirta P; Butzow R
Gynecol Oncol; 2003 Dec; 91(3):504-12. PubMed ID: 14675668
[TBL] [Abstract][Full Text] [Related]
38. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
39. [Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Spaček J; Cermáková E
Ceska Gynekol; 2013 Dec; 78(6):545-53. PubMed ID: 24372433
[TBL] [Abstract][Full Text] [Related]
40. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
